http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Jul 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html <p align="center"><i>Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.</i></p> <p align="center"><i>Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework</i></p> <p>BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform. The Company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult (CGT Catapult) Manufacturing Innovation Centre in Stevenage, UK, under http://www.streetinsider.com/Press+Releases/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html Mon, 20 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Press+Releases/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html <p align="center"><i>Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.</i></p> <p align="center"><i>Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework</i></p> <p>BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform. The Company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult (CGT Catapult) Manufacturing Innovation Centre in Stevenage, UK, under http://www.streetinsider.com/Press+Releases/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html Mon, 20 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html <p align="center"><i>Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.</i></p> <p align="center"><i>Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework</i></p> <p>BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform. The Company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult (CGT Catapult) Manufacturing Innovation Centre in Stevenage, UK, under http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html Mon, 20 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html <p align="center"><i>Commercial-Ready Manufacturing Now Supports Planned Phase 3 Confirmation Trial, and US, EU and UK Regulatory Submissions for Future Commercial Supply.</i></p> <p align="center"><i>Company Expresses Support for MHRA Draft Rare Disease Therapies Regulatory Framework</i></p> <p>BOCA RATON, Fla, July 20, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced a significant manufacturing milestone for its CORDStrom™ platform. The Company has successfully processed its first commercial-ready umbilical cord tissue at the Cell and Gene Therapy Catapult (CGT Catapult) Manufacturing Innovation Centre in Stevenage, UK, under http://www.streetinsider.com/Globe+Newswire/INmune+Bio+Completes+Commercial+Manufacturing+Milestone+Supporting+Planned+Global+Registration+Filings+for+CORDStrom%E2%84%A2+Platform/26786764.html Mon, 20 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Corporate+News/INmune+Bio+publishes+preclinical+study+on+XPro1595+and+brain+injury/26770721.html <p>INmune Bio, Inc. (NASDAQ: INMB) announced the publication of a peer-reviewed preclinical study in the Journal of Neurotrauma examining the biological link between traumatic brain injury (TBI) and Alzheimer's disease, according to a press release from the company.</p><p>The Department of Defense-funded study, conducted in 3xTg-AD mice, found that a single moderate TBI raised brain levels of tumor necrosis factor (TNF), its receptor TNFR1, and the neurotoxic protein amyloid beta (Aβ42). Animals that received the company's drug candidate XPro1595 showed reduced TNF levels, no injury-induced rise in Aβ42, improved learning and memory within one week of injury, and reduced pain compared http://www.streetinsider.com/Corporate+News/INmune+Bio+publishes+preclinical+study+on+XPro1595+and+brain+injury/26770721.html Wed, 15 Jul 2026 07:01:27 -0400 INMB http://www.streetinsider.com/FDA/INmune+Bio+publishes+preclinical+study+on+XPro1595+and+brain+injury/26770721.html <p>INmune Bio, Inc. (NASDAQ: INMB) announced the publication of a peer-reviewed preclinical study in the Journal of Neurotrauma examining the biological link between traumatic brain injury (TBI) and Alzheimer's disease, according to a press release from the company.</p><p>The Department of Defense-funded study, conducted in 3xTg-AD mice, found that a single moderate TBI raised brain levels of tumor necrosis factor (TNF), its receptor TNFR1, and the neurotoxic protein amyloid beta (Aβ42). Animals that received the company's drug candidate XPro1595 showed reduced TNF levels, no injury-induced rise in Aβ42, improved learning and memory within one week of injury, and reduced pain compared http://www.streetinsider.com/FDA/INmune+Bio+publishes+preclinical+study+on+XPro1595+and+brain+injury/26770721.html Wed, 15 Jul 2026 07:01:27 -0400 INMB http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html Wed, 15 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html Wed, 15 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html Wed, 15 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%27s+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770627.html Wed, 15 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html Wed, 15 Jul 2026 07:00:00 -0400 INMB O.39467908 http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Press+Releases/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html Wed, 15 Jul 2026 07:00:00 -0400 INMB O.39467908 http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html Wed, 15 Jul 2026 07:00:00 -0400 INMB O.39467908 http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html <p align="justify"><i>The study points to soluble TNF as a key biological link between head injury and Alzheimer’s disease and shows that selectively neutralizing it with XPro1595 prevents the injury-induced rise in amyloid pathology while improving early cognitive and pain-related outcomes.</i></p> <p align="justify">Boca Raton, FL, July 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a late-stage inflammation and immunology company, today announced the publication of a new peer-reviewed preclinical study in the Journal of Neurotrauma examining how traumatic brain injury (TBI) drives the biological changes that link head injury to Alzheimer’s disease (AD). The Department of http://www.streetinsider.com/Globe+Newswire/INmune+Bio%E2%80%99s+XPro1595+Prevents+Brain-Injury-Induced+Alzheimer%26apos%3Bs+Pathology%2C+Memory+Loss%2C+and+Pain+in+New+Peer-Reviewed+Preclinical+Study/26770678.html Wed, 15 Jul 2026 07:00:00 -0400 INMB O.39467908 http://www.streetinsider.com/FDA/INmune+Bio+to+present+Phase+2+imaging+data+for+XPro+at+AAIC+2026/26749901.html <p>INmune Bio Inc. (NASDAQ: INMB) announced new imaging data from its Phase 2 study of XPro in patients with early Alzheimer's disease, with a presentation scheduled at the Alzheimer's Association International Conference (AAIC) in London on July 12, 2026.</p> <p>The data showed a statistically significant treatment effect on white matter myelin integrity at Week 24 in the modified intent-to-treat population (p &lt; 0.01), with larger effects observed in patients selected using the company's biomarker enrichment strategy. These results were first reported by INmune Bio on June 2, 2026.</p> <p>The AAIC presentation will include a full chi-separation analysis of white matter myelin alongside http://www.streetinsider.com/FDA/INmune+Bio+to+present+Phase+2+imaging+data+for+XPro+at+AAIC+2026/26749901.html Thu, 09 Jul 2026 07:00:14 -0400 INMB http://www.streetinsider.com/Press+Releases/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html <p align="left"><em>Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.</em></p> <p><i>White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p &lt; 0.01), </i>with larger effects observed in patients selected using the company’s biomarker enrichment strategy.</p> <p><b>BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- </b> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its Phase 2 study of http://www.streetinsider.com/Press+Releases/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html Thu, 09 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Press+Releases/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html <p align="left"><em>Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.</em></p> <p><i>White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p &lt; 0.01), </i>with larger effects observed in patients selected using the company’s biomarker enrichment strategy.</p> <p><b>BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- </b> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its Phase 2 study of http://www.streetinsider.com/Press+Releases/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html Thu, 09 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html <p align="left"><em>Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.</em></p> <p><i>White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p &lt; 0.01), </i>with larger effects observed in patients selected using the company’s biomarker enrichment strategy.</p> <p><b>BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- </b> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its Phase 2 study of http://www.streetinsider.com/Globe+Newswire/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html Thu, 09 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/Globe+Newswire/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html <p align="left"><em>Advanced MRI analyses showed early treatment-related changes in white matter myelin integrity and cortical microstructure at Week 24, supporting biologic activity of selective soluble TNF inhibition.</em></p> <p><i>White matter myelin integrity demonstrated a statistically significant treatment difference at Week 24 in the modified intent-to-treat population (p &lt; 0.01), </i>with larger effects observed in patients selected using the company’s biomarker enrichment strategy.</p> <p><b>BOCA RATON, Fla., July 09, 2026 (GLOBE NEWSWIRE) -- </b> INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology company focused on inflammation and immunology, today announced new imaging data from its Phase 2 study of http://www.streetinsider.com/Globe+Newswire/INmune+Bio+to+Present+Positive+Phase+2+Imaging+Data+for+XPro+in+Early+Alzheimer%E2%80%99s+Disease+at+AAIC/26749868.html Thu, 09 Jul 2026 07:00:00 -0400 INMB INMB http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Juda+Scott/26738225.html si-local-file:///var/storage/secattach/20260707/26738225.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Juda+Scott/26738225.html Tue, 07 Jul 2026 07:02:00 -0400 INMB O.39467908 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Juda+Scott/26738225.html si-local-file:///var/storage/secattach/20260707/26738225.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Juda+Scott/26738225.html Tue, 07 Jul 2026 07:02:00 -0400 INMB O.39467908 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Lowdell+Mark+William/26738214.html si-local-file:///var/storage/secattach/20260707/26738214.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Lowdell+Mark+William/26738214.html Tue, 07 Jul 2026 07:01:00 -0400 INMB O.39467908 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Lowdell+Mark+William/26738214.html si-local-file:///var/storage/secattach/20260707/26738214.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Lowdell+Mark+William/26738214.html Tue, 07 Jul 2026 07:01:00 -0400 INMB O.39467908 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Moss+David+J/26738205.html si-local-file:///var/storage/secattach/20260707/26738205.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Moss+David+J/26738205.html Tue, 07 Jul 2026 07:00:00 -0400 INMB O.39467908 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Moss+David+J/26738205.html si-local-file:///var/storage/secattach/20260707/26738205.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inmune+Bio%2C+Inc.++++++++++For%3A+Jul+02++Filed+by%3A+Moss+David+J/26738205.html Tue, 07 Jul 2026 07:00:00 -0400 INMB O.39467908